ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
Different aspects of Pseudomonas aeruginosa biofilm: an in-depth analysis from formation to detection.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Short Synthetic Lipopeptides CAntibiotics (Basel, Switzerland) · 2026Article
- Clonal spread and environmental persistence of carbapenem-resistant high-riskMicrobial cell (Graz, Austria) · 2026Article
- A broad-host-range inhalable phage cocktail for treatment of multidrug-resistantFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Planktonic pathogens pose a significant threat to the global community, especially as they develop into microbial biofilms. Pseudomonas aeruginosa, a gram-negative bacillus, is notorious for causing nosocomial infections and can easily transform into a multidrug-resistant form, particularly within biofilms. This transformation leads to chronic infections in immunocompromised individuals, increasing morbidity and mortality rates worldwide. P. aeruginosa uses biofilms to survive, becoming robust and evading the host's immune protection system. Biofilms also shield microorganisms from antibiotics, rendering them drug-resistant and causing treatment failures. P. aeruginosa biofilms are often associated with device-related infections, as indwelling medical devices (IMDs) serve as breeding grounds for microbial biofilm growth. The ubiquitous presence of P. aeruginosa on both living and abiotic surfaces makes it an excellent model for studying biofilms. The virulence factors of P. aeruginosa, such as lipopolysaccharides, pili, flagella, adhesins, and exopolysaccharides, facilitate disease progression and contribute to biofilm development and maturation. This review focuses on analyzing the characteristics of P. aeruginosa biofilms, including antimicrobial resistance and gene regulation. Methods for detecting biofilms are also briefly described. Additionally, this review provides a comprehensive exploration of the most effective methods for preventing and controlling microbial biofilms, particularly those formed by P. aeruginosa. This study aims to inspire future research and the development of innovative technologies to resist microbial adherence, colonization, and biofilm formation.
Indexed as
Identifiers
40042559What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.